Catalyst Biosciences Inc(BHVN)stock report

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company’s glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer’s disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.

Finance:
Market Cap:300M; Shares Outstanding:52.2M; Short Interest: 15.11%; Q3 2019(9/30/19): Cash 417M. Loss 107M

EPS and Sales:
https://finance.yahoo.com/quote/BHVN/financials?p=BHVN

Date EPS % last year % last quarter
2018.12.31 -6.15 -23.00% -27.59%
2019.3.31 -1.41 39.22% 77.07%
2019.6.30 -6.11 -85.71% -329.00%
2019.9.30 -8.04 -66.81% -31.59%

 

Sale:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=BHVN&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/BHVN/institutional-ownership/

2019.12.20:
Total institutions: 230,no change
Shares hold: 5099.41k shares. no change
shares% hold: 97.61%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/BHVN/price-targe

Leave a Reply